-
Sector Analysis
Hodgkin Lymphoma: Epidemiology Report and Forecast to 2035
Hodgkin lymphoma (HL) is a type of lymphoma, a cancerous condition that affects the lymphatic system and occurs in both children and adults. HL is a rare disease that starts with abnormal growth of the white blood cells, called lymphocytes, and then spreads beyond the lymphatic system and impairs the body’s immune system. The exact cause of HL is unclear; however, 20–40% of HL cases had a prior diagnosis of infectious mononucleosis caused by the Epstein-Barr virus (EBV). HL originates...
-
Sector Analysis
Glioblastoma (GBM): Epidemiology Report and Forecast to 2035
Glioblastoma multiforme (GBM) is a highly aggressive form of glioma, a cancer arising from astrocytes, and is the most common type of brain tumor in adults (Kanderi et al., 2024). The distinction of “multiforme” comes from the wide range of genetic expressions characteristic of the cancer, complicating treatment (Kanderi et al., 2024). Glioblastoma multiforme is currently incurable, with a median survival time of 15 months and a 7.2% five-year survival rate (Kanderi et al., 2024). Gold standard treatment is a...
-
Sector Analysis
Narcolepsy Major Markets: Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2035
This report covers the 7 major markets and provides an Excel-based forecast model for the narcolepsy market through 2035 The narcolepsy therapeutics market totaled $4.6 billion in 2025 across the seven major markets (7MM: the US, France, Germany, Italy, Spain, the UK, and Japan). It is projected to grow rapidly at 5.5% compound annual growth rate (CAGR) to $7.8 billion by 2035, mainly driven by the entry of orexin agonists from the late-stage pipeline, the introduction of new formulations, and...
-
Sector Analysis
Narcolepsy: Epidemiology Report and Forecast to 2035
Narcolepsy is a chronic neurological disorder that affects the brain’s ability to control sleep-wake cycles, making people very sleepy during the day (Mayo Clinic, 2024; National Institute of Neurological Disorders and Stroke, 2026). Some patients also have other symptoms, such as muscle weakness when they feel strong emotions, which is known as cataplexy. Narcolepsy can disrupt daily life, making it hard to work, study, or maintain relationships. Narcolepsy is an uncommon but manageable lifelong condition (Cleveland Clinic, 2025). There are...
-
Sector Analysis
Microbiome-Based Medicinal Products: Poised for Progress Despite Uncertain Regulatory Environment
Following on from the US FDA's approval of Ferring's (Switzerland) microbiome-based medicinal product (MBMP) Rebyota (fecal microbiota, live) in November 2022, only three other MBMPs have been approved in developed markets around the world. However, this bare statistic belies the intensive R&D activity that has been taking place beneath the surface, with more than a dozen MBMP candidates currently undergoing late-stage clinical trials. Moreover, while the four approved products are all indicated for preventing the recurrence of Clostridioides difficile (C. difficile) infection...
-
Product Insights
Atopic Dermatitis (Atopic Eczema) - Global Clinical Trials Review, 2026
GlobalData's clinical trial report, “Atopic Dermatitis (Atopic Eczema) - Global Clinical Trials Review, 2026" provides an overview of Atopic Dermatitis (Atopic Eczema) Clinical trials scenario. This report provides top line data relating to the clinical trials on Atopic Dermatitis (Atopic Eczema). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and...
-
Product Insights
Multiple Myeloma (Kahler Disease) - Global Clinical Trials Review, 2026
GlobalData's clinical trial report, “Multiple Myeloma (Kahler Disease) - Global Clinical Trials Review, 2026" provides an overview of Multiple Myeloma (Kahler Disease) Clinical trials scenario. This report provides top line data relating to the clinical trials on Multiple Myeloma (Kahler Disease). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and...
-
Product Insights
Age Related Macular Degeneration - Global Clinical Trials Review, 2026
GlobalData's clinical trial report, “Age Related Macular Degeneration - Global Clinical Trials Review, 2026" provides an overview of Age Related Macular Degeneration Clinical trials scenario. This report provides top line data relating to the clinical trials on Age Related Macular Degeneration. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and...
-
Product Insights
Duchenne Muscular Dystrophy - Global Clinical Trials Review, 2026
GlobalData's clinical trial report, “Duchenne Muscular Dystrophy - Global Clinical Trials Review, 2026" provides an overview of Duchenne Muscular Dystrophy Clinical trials scenario. This report provides top line data relating to the clinical trials on Duchenne Muscular Dystrophy. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report...
-
Product Insights
Idiopathic Inflammatory Myopathy (IIM) - Global Clinical Trials Review, 2026
GlobalData's clinical trial report, “Idiopathic Inflammatory Myopathy (IIM) - Global Clinical Trials Review, 2026" provides an overview of Idiopathic Inflammatory Myopathy (IIM) Clinical trials scenario. This report provides top line data relating to the clinical trials on Idiopathic Inflammatory Myopathy (IIM) . Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.